Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - terlipressin acetate 0.2 mg/ml equivalent to terlipressin 0.17mg/ml;   - solution for injection - 2 mg/10ml - active: terlipressin acetate 0.2 mg/ml equivalent to terlipressin 0.17mg/ml   excipient: glacial acetic acid hydrochloric acid sodium chloride sodium hydroxide water for injection - indicated for: - the treatment of bleeding oesophageal varices (bov); and - type 1 hepatorenal syndrome, characterised by spontaneous acute renal insufficiency, in patients suffering from severe cirrhosis with ascites.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

everybody labo limited - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - to help reduce bacteria on the skin.

Unia Europejska - angielski - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - diabetes mellitus, type 2 - drugs used in diabetes - rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Malta - angielski - Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Malta - angielski - Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Izrael - angielski - Ministry of Health

j-c health care ltd - amivantamab - concentrate for solution for infusion - amivantamab 350 mg / 7.0 ml - amivantamab - rybrevant is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion mutation, as detected by an approved test whose disease has progressed on or after platinum-based chemotherapy.

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn. bhd. - amivantamab -

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - amivantamab 50 mg/ml - concentrate for infusion - active: amivantamab 50 mg/ml excipient: disodium edetate dihydrate histidine histidine hydrochloride monohydrate methionine polysorbate 80 sucrose water for injection - rybrevant has provisional approval for the treatment of adults patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that has an activating epidermal-growth factor receptor (egfr) exon 20 insertion mutation whose disease has progressed on or after platinum-based chemotherapy.

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - esomeprazole - tablets gastro-resistant - 20 milligram - proton pump inhibitors

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - esomeprazole - tablets gastro-resistant - 40 milligram - proton pump inhibitors